title: Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
authors.forename: Xabier
authors.initials: X
authors.lastname: Agirre
authors.forename: Ana
authors.initials: A
authors.lastname: Fontalba
authors.forename: Enrique J
authors.initials: EJ
authors.lastname: Andreu
authors.forename: Maria Dolores
authors.initials: MD
authors.lastname: Odero
authors.forename: María José
authors.initials: MJ
authors.lastname: Larráyoz
authors.forename: Cristina
authors.initials: C
authors.lastname: Montiel
authors.forename: María José
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: José Luis
authors.initials: JL
authors.lastname: Fernández-Luna
authors.forename: Felipe
authors.initials: F
authors.lastname: Prósper
mesh_terms: D019943:Amino Acid Substitution; D001549:Benzamides; D002999:Clone Cells / Q000737:chemistry / Q000648:ultrastructure; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics*; D020125:Mutation, Missense; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D017434:Protein Structure, Tertiary / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D004273:DNA, Neoplasm; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl